🔗 Share this article

An underground market for unapproved weight-loss drugs is being driven by social media fitness personalities and vendors on messaging platforms, according to new investigations.

Investigational Drug Gaining Traction Via Social Media

The experimental drug, which is still in clinical trials, is being promoted by online personalities for its alleged weight-reducing effects. Followers are encouraged to contact these accounts directly for source information, while also obtaining promotional offers.

Thriving Trade on Social Networks

Additionally, a flourishing market exists on messaging services, where communities with thousands of members share “before and after” photos, administration instructions and assertions of next-day UK delivery. Sellers market the substance there before directing buyers to WhatsApp for purchases.

Understanding The Experimental Drug

This medication is an investigational injectable created by American pharmaceutical company Eli Lilly. The treatment targets three intestinal hormones – glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and pancreatic hormone. Preliminary studies suggest it could assist patients reduce up to a quarter of their total weight. Referred to as the “triple G”, the substance is being hailed online as the successor to Ozempic.

Medical Professionals Express Concerns

However, doctors and chemists have cautions that the sale of what remains an unapproved drug in the UK is worrisome and could lead to users injecting products of unknown origin.

Several professionals stated the popularity for the experimental drug could be connected to the rising cost of approved weight loss products such as Mounjaro.

Regulatory Position and Enforcement

Marketing the unapproved drug on TikTok or messaging apps is illegal in the United Kingdom, as it is an unlicensed medication that must not be promoted or distributed for personal consumption under the British medical regulations.

Some content creators try to sidestep the regulations by referring to the substance as a “research chemical” or describing it as “not for human consumption”. Retatrutide is not a controlled drug, but promotion and supply can still violate medicines, marketing, and consumer regulations, risking penalties, legal action or imprisonment.

Service Reaction and Material Elimination

Based on the social media company, the platform has taken down violative content and prohibited related keywords and query recommendations. The organization said it was committed to keeping the platform secure and allocating resources in enhancing enforcement strategies.

Digital Trading Activities

Investigations also found communities with up to 9,000 participants selling retatrutide using Telegram's integrated discovery tool, which functions like a online catalog. Entering “retatrutide” instantly brings up groups with thousands of members, populated with images of weight loss, glowing reviews and detailed instructions for mixing or administering at home.

Within moments of joining one community, a vendor posted contact information, where most transactions occur. The seller sent an instruction manual and promised delivery within 48 hours. When questioned whether the substance was authentic, one vendor said: “You can’t be sure.” Another provided a image of a alleged laboratory certificate. Not one asked about weight, health issues or past usage.

Item Information and Pricing

Inside these communities, posts show dark colored packages with postal service labels, claiming to include new batches. One message read: “It took eight of us to load them this morning.”

Buyers can choose between dry substance containers, mixed at home with sterile water, or pre-filled pens usually sold at 160 pounds for 20mg. When questioned how long a pen should be used, sellers give contradictory answers varying between a several days to “depends on your body”.

Service Moderation and Security Actions

A spokesperson for Telegram said it actively monitored dangerous material on its platform including material that encouraged the “misuse of controlled medications”. The company noted that it eliminated “millions of pieces of harmful content each day”.

Medical Expert Warnings

“People are injecting substances they cannot confirm. Even if the science behind this drug is valid, these digital products may not include what they advertise,” said a pharmacy expert, the head of pharmacy at Chemist4U.

Dr Crystal Wyllie of an online medical service linked the surge in demand to current price rises for approved weight-loss drugs such as Mounjaro. “With prices rising, patients are using online platforms. But fake treatments are highly risky. You can’t be certain what’s inside or whether the conditions they were made in was sterile,” she explained.

Her team has already seen individuals injured by personal administration from unverified sources. “We understand the disappointment, but buying from messaging apps or WhatsApp is taking chances with your well-being,” said Wyllie. “These materials could be contaminated or improperly measured.”

Producer Position

A spokesperson from Eli Lilly said retatrutide was in third stage research studies and had not been reviewed or authorized by any regulatory agency globally. “Consequently at this point no one can sell [it] for personal consumption,” they said, adding that any product “falsely representing itself as a company experimental product not yet authorized … may expose patients to potentially significant medical dangers”.